Metelimumab (CAT192) is a human IgG4 monoclonal antibody developed as a TGFb1-specific antagonist. It was tested in clinical trials for the treatment of scleroderma but later terminated due to lack of efficacy. Subsequent characterization of CAT192 indicated that its TGFb1 binding affinity was reduced by »50-fold upon conversion from the parental single-chain variable fragment (scFv) to IgG4. We hypothesized this result was due to decreased conformational flexibility of the IgG that could be altered via engineering. Therefore, we designed insertion mutants in the elbow region and screened for binding and potency. Our results indicated that increasing the elbow region linker length in each chain successfully restored the isoformspecific and high affinity binding of CAT192 to TGFb1. The crystal structure of the high binding affinity mutant displays large conformational rearrangements of the variable domains compared to the wild-type antigen-binding fragment (Fab) and the low binding affinity mutants. Insertion of two glycines in both the heavy and light chain elbow regions provided sufficient flexibility for the variable domains to extend further apart than the wild-type Fab, and allow the CDR3s to make additional interactions not seen in the wild-type Fab structure. These interactions coupled with the dramatic conformational changes provide a possible explanation of how the scFv and elbow-engineered Fabs bind TGFb1 with high affinity. This study demonstrates the benefits of re-examining both structure and function when converting scFv to IgG molecules, and highlights the potential of structure-based engineering to produce fully functional antibodies.
Introduction
Transforming growth factor b (TGFb) is a multifunctional cytokine that controls a wide array of biological processes, including cellular proliferation, differentiation, migration and apoptosis. 1 With such an extensive role in the cell, TGFb has been linked to several diseases when it is not properly regulated. For instance, an increased level of TGFb in tissues is believed to be a factor in the development of idiopathic pulmonary fibrosis and myocardial fibrosis. 2, 3 Furthermore, TGFb has been linked to solid and hematopoietic tumors. 4 As an inhibitor of cell growth, TGFb has a pro-apoptotic effect on tumor cells, thus acting as a tumor suppressor. However, many tumor cells respond to TGFb as an oncogenic factor. Therefore, TGFb may act as a tumor suppressor or a pro-tumorigenic factor depending on tumor type and stage. 4, 5 There are three TGFb isoforms in humans (TGFb1, TGFb2, and TGFb3), which all signal through the same serine/threonine kinase type I and type II cell surface receptors. 4, 6 While having similar cellular targets, biological studies have demonstrated that the isoforms have different expression profiles. Of the three isoforms, TGFb1 is the most abundant and ubiquitously expressed. 4 Metelimumab, also known as CAT192, is a human IgG4 monoclonal antibody that was designed to selectively neutralize TGFb1. CAT192 was tested for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma, but demonstrated insufficient efficacy. 7 The elbow region of an antibody is a linker that joins the variable domains (VL and VH) and the constant domains (CL and CH1) of the molecule's antigen-binding fragment (Fab). 8 The range of flexibility of the elbow region in an IgG molecule allows the Fab arms to adopt a range of angles, which permits binding to epitopes that are separated by certain distances. 9, 10 It was also demonstrated that the elbow region can be an important functional element of antibody structure, and that integrity of the joint between variable and constant domains is essential for complete activity of a humanized antibody.
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CAT192, however, was derived from a scFv library, and variable domains in a scFv molecule are joined directly by a linker that is typically longer than a Fab elbow region. 12, 13 The longer linker in the scFv may allow the variable domains to be separated in a conformation that is not possible in the restricted elbow region of the Fab molecule.
We aimed to engineer the flexibility/affinity back in the Fab or IgG versions of the CAT192 scFv by adding additional amino acids in the elbow region. These constructs with varying linker lengths were analyzed for their affinity, efficacy, and thermal stability. The crystal structures were determined for selected constructs to demonstrate the conformational changes of the engineered antibodies. This study shows that engineering an ideal number of residues into the elbow region can restore the binding affinity that is lost during the scFv to IgG conversion.
Results

Binding studies of CAT192 scFv and IgG
Biacore experiments showed CAT192 scFv to bind TGFb1 at 2.8 § 1.41 nM (Fig. 1A) , whereas no binding was detected against TGFb2 or TGFb3 (Supplementary Fig. 1A ). However, when CAT192 scFv was converted to IgG4, a significant decrease in affinity to TGFb1 was observed (K D D 138.6 § 33.51 nM) (Fig. 1B) . In addition, conversion to IgG1 or Fab also displayed very weak binding to TGFb1 (Fig. 1C and 1D) , showing K D s of 524 nM and 443 nM, respectively. This indicates that the subtype and Fc format was not responsible for this phenomenon. The CAT192 single-chain molecule contains a long (SSGGGSGGGGSGGGGS) linker connecting the heavy and light chain Fv domains. This flexible linker is lost in the conversion to IgG. A slight improvement in TGFb1 binding was observed when CAT192 was treated with urea, suggesting that conformation change or flexibility may play a role in the observed affinity differences (Supplementary Fig. 1C ).
Design and characterization of CAT192 Fab variants
Site-directed mutagenesis was performed aiming to introduce flexibility into the Fab versions. For the first round of Fab mutations, additional amino acids were inserted in the light chain (LC) elbow region. More specifically, mutants were designed to add one glycine (L1), two glycines (L2), two glycines and one serine (L3), three glycines and one serine (L4), and four glycines and one serine (L5) sequences into the wild type (WT) light chain elbow region ( Table 1 ). The light chain mutants bound to TGFb1 with a significantly increased affinity compared to the WT CAT192 Fab (Table 2) . These results show a step-wise improvement in TGFb1 binding with the insertion of each additional residue into the elbow region of the Fab. None of the CAT192 LC Fab mutants bound to TGFb2 or TGFb3 (result not shown), demonstrating that the mutants retained isoform-selectivity.
For the second round of mutations, constructs were designed inserting additional amino acids in the heavy chain (HC) elbow region of CAT192 Fab. Like the light chain mutants, either one glycine (H1), two glycines (H2), or four glycines and a serine (H5) sequences were added into the wildtype heavy chain elbow region ( Table 1 ). The results (Table 2) show that addition of amino acids in the elbow region of CAT192 HC also improves TGFb1 binding. Like the light chain mutants, these mutants were also shown to be isoform-specific (result not shown).
Since the binding affinity of CAT192 Fab to TGFb1 improved with insertion of additional amino acids into the elbow regions of the HC or LC, different HC and LC mutant combinations were tested next. Twenty-three variants plus WT were tested for their binding affinity to TGFb1 (Table 2 , Fig. 2 ). Combining the HC and LC insertion mutants also restored TGFb1 binding affinity; however, there was a saturation effect with the number of insertions. For example, the combination of "HCCG" and "LCCGG" (H1/L2) mutants showed one of the highest affinity binding (2.6 nM) to TGFb1, which was the same as combining the "HCCGGGGS" and "LCCGGGGS" (H5/L5) insertions (Table 2 ).
Affinity and potency characterization of IgG4 variants
The HC and LC insertion mutants were converted to an IgG4 format in order to confirm that the affinity to TGFb1 was regained. The H2/L2 mutant was also included for comparison with the single-arm insertion mutants. Surface plasmon resonance (SPR) analysis of the CAT192 IgG4 insertion mutants agrees with the Fab mutant results that TGFb1 binding affinity is regained when amino acids are added to the elbow regions of the heavy and light chains (H2/L2 IgG4 K D D 0.2 nM). None of the mutants were seen to bind TGFb2 or TGFb3 ( Supplementary Fig. 2 ). The regained affinity for H2/L2 IgG4 is within the range of known therapeutic TGFb antibodies, such as fresolimumab (K D D 1.7 nM). 14 The CAT192 IgG4 insertion mutants were then characterized in an A549 bioassay to measure the TGFb1 neutralization activity. 15 The potency assay is based on the TGFbinduced release of interleukin-11 (IL-11) by the human lung epithelial cell line A549. When one glycine was added to the LC, the potency of CAT192 to neutralize TGFb1-stimulated IL-11 production was improved compared with the weak activity demonstrated by CAT192 WT (Fig. 3A) . Addition of one glycine in the HC had a greater effect on the potency of CAT192 than when it was added in the LC (Fig. 3B ). Among the tested mutants, the H2/L2 mutant had the highest potency (Fig. 3B ).
Stability assessment of CAT192 insertion variants
Differential scanning fluorimetry (DSF) was performed on the insertion mutants to determine how the additional amino acids at the elbow region affected thermostability. Melting temperatures (T m s) were calculated from the unfolding patterns of each mutant, and are shown in Fig. 4 . The results show that the relative stability of the CAT192 Fab insertion mutants decreases slightly with the insertion of additional residues in the elbow regions of the heavy and light chains. The T m s of some of the longer chain mutants could not be calculated due to the unfolding pattern. Slight decreases in stability was also observed when some of the light chain mutants were converted from Fab into the IgG4 format (Fig. 4B ).
Structural analysis of CAT192 Fab variants
To understand how each elbow length affected binding, the structures of multiple CAT192 elbow variant Fabs with varying affinities to TGFb1 were solved using x-ray crystallography. The constructs chosen were WT CAT192 (H0/ L0), a low binding affinity mutant (H0/L1), a moderate binding affinity mutant (H5/L0), and a high binding affinity mutant (H2/L2). Wild type, H0/L1, and H5/L0 all crystalized similarly in a PEG condition at neutral pH. Conversely, H2/L2 only crystallized in an ammonium sulfate condition and in a more acidic pH (Table 3) .
Superposition of each Fab on the constant domain shows dramatic conformational changes between the high affinity mutant and the other lower binding affinity Fab constructs. While the relative orientations of the variable domain consistently differ between H2/L2 and the other crystallized constructs, the other variants (H0/L1 and H5/L0) show a similar orientation to wild type (Fig. 5 ). The WT Fab and the two other low/moderate binding affinity structures show little variation and superimpose with WT with an overall root-mean-square Table 2 . TGFb1-binding affinity of the heavy and light Chain combination mutants determined by biacore.
WT HC/WT LC H0/L0 TGFb1 n/a n/a n/a WT HC/LCCG H0/L1 TGFb1 n/a n/a n/a WT HC/LCCGG H0/L2 TGFb1 0. for H0/L1 and H5/ L0, respectively. In contrast, WT CAT192 and H2/L2 superimpose with a R.M.S.D. of 8.941A (Fig. 6A) . The H2/L2 elbow insertion also brings about large changes in the antigen binding interface. While the variable domains of WT CAT192 cover a distance of »50A (Fig. 6B) , the rotation of the variable domains in H2/L2 causes the domains to display a distance of 70A between the same residues (Fig. 6C ). This length is measured from two distal residues: HC S75 and LC G16. Furthermore, in the WT structure, the distance between HC and LC complementary-determining regions (CDRs) are 27A , 22A
, and 16A for CDR1, CDR2, and CDR3, respectively (Fig. 6B) . With the H2/L2 elbow insertion, the CDR3s are much closer at a distance of 10A , while CDR1s are 25A apart and CDR2s are 36A apart. The closer association of the CDR3 loops in the high binding affinity mutant allows CDRH3 to make additional hydrophobic interactions and hydrogen bonds with CDRL3. This CDR3 interface may be important for binding to the TGFb1 epitope. Furthermore, the high binding affinity H2/L2 structure is the only CAT192 Fab structure where the CDRH3 region is completely ordered.
Discussion
Antibody re-formatting from parental scFv and Fab to IgG is a common practice in antibody research and development. It has been demonstrated that phage display-based affinity maturation of IgGs could be dependent on the antibody format employed for selection and screening. 16 A problem that may be commonly seen during antibody generation, but not always reported, is the loss of antigen binding affinity during these scFv to IgG conversions. [17] [18] [19] This was observed when CAT192 scFv was converted to CAT192 Fab and IgG4. CAT192 IgG4 displayed a significant decrease in K D compared to CAT192 scFv (K D D 138.6 nM vs. 2.8 nM). This low affinity is characterized by a very slow on-rate (k a D 0.01
One explanation of the slow onrate could be that TGFb1 may require a potential induced fit conformational change, and, once bound, the complex is stable, as characterized by a very slow off-rate. The scFv contains much more structural flexibility between its variable domains because the domains are joined by a large linker. However, the Fab and IgG molecules are subject to the constraints of the elbow linker that anchor the variable domains. Thus, we proposed and tested the hypothesis in this study that the ability of the variable domains to adopt different conformations, due to different structural constraints in scFv and Fab/IgG, can have an impact on binding affinity.
The flexibility of the elbow region allows the Fab arm to adopt a certain range of angles, which allows binding to epitopes whose variable domains are spaced certain distances apart. In this study, site-directed mutagenesis was performed on the CAT192 elbow regions to improve TGFb1 binding affinity. This strategy was supported by a study where the elbow angles for 365 different Fabs were studied and compared. 13 Standfield et al. observed that λ light chains adopt a wider range of elbow angles compared to k light chains. The authors proposed that the hyperflexibility in the λ light chain may be due to an insertion in their elbow region, which was one residue longer than in k chains and typically a glycine. Our study theorized that the elbow region in CAT192 Fab or IgG4 needs to be relaxed to allow an extended conformation between the variable domains (such as seen in the scFv). The wild type CAT192 constructs had the weakest binding affinity for TGFb1 in this study. For the antibodies with wild type HC/LC insertions, the affinity increased with additional residues added in the light chain. For the reverse antibody combination (wild type LC/HC insertions), affinity also increased with additional residues in the elbow region. This demonstrates that affinity increases with additional flexibility introduced into each chain. Interestingly, for the combination HC/LC insertion mutants, saturation was reached in terms of affinity. The affinity did not improve drastically after two glycines were introduced into each chain at the Statistics for the highest-resolution shell are shown in parentheses. elbow region. Also, a trade off was observed between stability and affinity. As the number of residues inserted for each individual chain increased, a decrease was observed in the melting temperature. This may be due to reduced stabilization of the CH1/CL domains.
To confirm that this increase in binding affinity was due to increased flexibility of the antibody's elbow region, the structures were solved for select mutants. Wild type CAT192 Fab superimposed with similar low R.M.S.D. values to the H0/L1 and H5/L0, indicating high structure similarity. The H2/L2 variant superimposed with WT with a much higher R.M.S.D. than either of the previous variants, demonstrating a much larger conformational change between the constructs. Accordingly, an increase in R.M.S.D. correlated with an increase in binding affinity to TGFb1. Since binding affinity and structural change show a direct correlation, this suggests the antibody must undergo considerable conformational arrangement to accommodate antigen binding. This change can occur by displacement of variable domains or rearrangement of CDR loops. With an increase in elbow angle rotation due to increase in length and flexibility, the variable domains can adopt a larger range of conformations.
The fact that variable domains are spaced much more apart in H2/L2, and this mutant binds TGFb1 with the highest affinity, suggests at least two possibilities. The first possibility is that the epitope on TGFb1 is more elongated than the WT CAT192 can accommodate. Only when the elbow region is relaxed can the variable domains adopt the conformation needed to encompass this large epitope. This is why wild-type CAT192, even though it has the same CDR sequences as the H2/L2 variant, would bind with the lowest affinity: the molecule's restricted elbow region does not allow it to adopt the conformation needed for binding. When the elbow region was engineered to accommodate more flexibility, high affinity binding to TGFb1 retained. The second possibility is that only one chain participates in the binding and the second chain is sterically hindering the binding interaction. When the elbow region sequence is longer, it allows the inhibitory chain to essentially move out of the way for antigen binding.
Fresolimumab is a pan-specific TGFb antibody. High-resolution structures of the scFv or Fab forms fresolimumab bound to all three TGFb isoforms have been determined. (Fig. 7) . We know CAT192 H2/L2 must bind TGFb1 in a different way than fresolimumab since WT CAT192 (which has the highest similarity to fresolimumab) does not bind TGFb1 with high affinity. Size-exclusion chromatography combined with multi-angle light scattering (SEC-MALS) was run to understand what molar ratio CAT192 H2/L2 binds to TGFb1. The complex elutes at a molecular weight of 129.6 kDa, corresponding to the weight of one TGFb1 dimer with 2 Fab molecules (data not shown). This is the same stoichiometry as fresolimumab; thus, CAT192 H2/L2 must have a different epitope or mechanism of action.
Our results suggest that conformational changes in therapeutic antibodies could have an effect on binding affinity in general, and thus need to be carefully examined. This case study shows that inserting linker residues in the elbow region of the converted Fab and IgG molecule increases flexibility, and thus affinity. Our work demonstrates the benefits of structural and functional re-examination when converting scFv to IgG molecules and highlights the potential of structure-based engineering to produce fully functional antibodies.
Materials and methods
Construction and expression of CAT192 variants
CAT192 Fab and IgG4 expression plasmids were constructed by cloning the variable heavy and light chain sequences from CAT192 into the episomal expression vector, pFF. 21 The DNA sequences were ordered from GeneArt after optimizing for HEK293 expression. A six residue Histag was added to the HC of the Fab for purification purposes. Primers were designed and ordered from Invitrogen. The QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) was used to add one glycine (G), two glycines (GG), two glycines and one serine (GGS), three glycines and one serine (GGGS), or four glycines and one serine (GGGGS) sequences into the CAT192 wild type LC or HC elbow region. All plasmid DNA was prepared with Qiagen kits and sequences were confirmed. The CAT192 LC or HC variants were co-expressed using the Expi293F transfection systems (Life Technologies) and conditioned media was harvested 4 days post-transfection. Expression in conditioned media was analyzed using an Octet QK384 biosensor (Pall Fort eBio).
Purification of CAT192 Fab variants for TGFb binding assessment
The CAT192 Fab variants in conditioned media were purified using PureSpeed IMAC tips (Rainin). The resin was equilibrated and washed in 10 mM sodium phosphate pH 7.4, 300 mM NaCl, 3 mM imidazole, and the protein was eluted in 10 mM sodium phosphate pH 7.4, 300 mM NaCl, 250 mM imidazole pH 7.4. The samples were buffer exchanged using Amicon Ultra filters (Millipore) into Gibco phosphate-buffered saline (PBS) pH 7.2 (Invitrogen) after the elution step.
Purification of CAT192 IgG variants for affinity and potency characterization
The CAT192 IgG4 variants were purified from conditioned media using Hi-Trap Protein A HP columns (GE Healthcare) with a peristaltic pump. The columns were equilibrated and washed with 50 mM sodium phosphate, 25 mM NaCl pH 7.1. A more stringent wash was performed in 10 mM sodium succinate pH 6.0, and the proteins were eluted in 10 mM sodium succinate pH 3.75. The eluates were neutralized with 0.2 M sodium hydroxide, and 0.2 M NaCl was added for a final concentration of 40 mM NaCl. The samples were then concentrated and buffer exchanged into 50 mM sodium phosphate, 25 mM NaCl pH 7.1 using Amicon Ultra filters (Millipore). 
Surface plasmon resonance biosensor analysis
The Biacore T200 instrument (GE Healthcare) was used to assess the TGFb binding affinity of the purified CAT192 WT and mutants. TGFb1 and TGFb2 were prepared and purified according to previously published procedures. 22, 23 TGFb3 was purchased from R&D Systems. Each isoform was immobilized to a CM5 series S chip using the amine coupling kit (GE Healthcare). To determine the binding affinities, low density chips were prepared in order to minimize avidity effects from binding to the immobilized TGFb homodimers. High-density chips were prepared to compare CAT192 WT binding. CAT192 (metelimumab) was tested in early experiments (Fig. 1B and Supplementary Fig. 1C ) and the CAT192 IgG4 S228P construct was used for all other analysis. The S228P mutation was used to reduce Fab arm exchange. 24 CAT192 WT and mutant Fabs or antibodies were always diluted the in HBS-EPC running buffer (GE Healthcare). The surface was regenerated with 40 mM HCl as described previously.
14 Binding sensorgrams were fit to a 1:1 binding model using the BiaEvaluation software (GE Healthcare) or Scrubber (BioLogic Software) to calculate binding affinities.
Cell potency assay
The CAT192 insertion mutants were characterized in an in vitro potency assay as described previously. 15 TGFb-induced interleukin-11 (IL-11) release from A549 human lung epithelial cells (ATCC) was measured by ELISA in this bioassay. IL-11 production was neutralized by anti-TGFb antibodies. Briefly, WT CAT192 and mutants were serially diluted 10-fold in growth/assay medium in a 96-well plate for final concentrations of 0.5 pg/mL to 50 mg/mL in duplicate. TGFb1 was then added to all of the wells to a final concentration of 0.3 ng/mL or 1 ng/ mL and incubated in a 37 C humidified tissue culture incubator for 1 hour. The TGFb1/CAT192 solution was then added to plated A549 cells and returned to the incubator overnight. An ELISA was then performed on the cell supernatants using an in-house human IL-11 ELISA to measure cytokine levels.
Differential scanning fluorimetry analysis
The Fab or IgG molecules were diluted to 0.1 mg/mL or 0.25 mg/mL in PBS pH 7.2 in duplicate and mixed with Sypro orange dye (Invitrogen) at a 1:4000 or 1:2000 dye ratio. The samples were heated from 20 to 100 C at a rate of 5 C/min using a CFX96 Real-Time PCR system (Bio-Rad). The T m values were calculated using the Bio-Rad CFX Manager 3.0 software.
Purification of CAT192 Fab variants for structure determination
The CAT192 Fab variants in conditioned media were purified using a HisTrap excel column (GE Healthcare) equilibrated with 20 mM sodium phosphate pH 7.4, 500 mM NaCl, 5 mM imidazole. Proteins were eluted with 20 mM sodium phosphate pH 7.4, 500 mM NaCl, 500 mM imidazole and immediately buffer exchanged into 20 mM HEPES pH 7.0, 50 mM NaCl over a size exclusion chromatography column (Superdex 200 10/300 GL; GE Healthcare) as a final preparative step for crystal trials.
Crystallization and structure determination of CAT192 Fab variants
The CAT192 variants were concentrated to 20 mg/mL and sparse matrix screens were set-up using the sitting drop vapor diffusion method. Each variant crystallized at 4 C and in a different condition (Table 3) . Crystals were cryo-protected in either 20% ethylene glycol (WT, H0/L1, H5/L0) or a gradient of 10-60% supersaturated lithium sulfate diluted in the mother liquor (H2/L2). All data sets were collected with a Rigaku FREC SuperBright generator and Saturn 944C CCD detector and processed with iMosflm followed by Scala in the CCP4 package. 25, 26 Wild-type CAT192 Fab was solved first and used 4G5Z HC & 3SKJ LC as search models for molecular replacement in Phaser. 27 The rest of the constructs used the WT CAT192 structure as a molecular placement model. Iterative model building and refinement were performed using phenix. refine and Coot. 28, 29 Statistics of the structure are summarized in Table 3 . All R.M.S.D values and atomic distances were calculated using PyMOL. Software used in this project was accessed through the SBGrid consortium. 30 Atomic coordinates have been deposited in the Protein Data Bank under accession codes 6AMJ (WT CAT192 Fab), 6AMM (H0/L1), 6ANP (H5/L0), and 6AO0 (H2/L2).
SEC-MALS
The molar mass of the CAT192 H2/L2:TGFb1 complex was determined using SEC-MALS (WYATT miniDAWN Treos MALS device and Optilab rEX). The column (Superdex 200 10/ 300 GL; GE Healthcare) was equilibrated with 20 mM sodium acetate pH 5.0, 50 mM NaCl. To form the complex, CAT192 H2/L2 was added to TGFb1 in a 2:1 ratio and incubated at 4 C overnight. Data were evaluated using the software ASTRA 6.1.
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